Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 6 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Mirati Therapeutics Inc. holds a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. There are currently 8 pending office actions within this portfolio, and these are assigned to 8 distinct examiners. This distribution between actions and examiners suggests that no single examiner is currently overwhelmed by the company's filings. The prosecution activity is further divided among 6 distinct art units, indicating a variety of pharmaceutical or biological classifications.
The busiest examiner, WELLS, LAUREN QUINLAN, is responsible for 1 busiest examiner pending office action. Because each of the 8 distinct examiners appears to be handling only 1 action, the designation of a busiest examiner is based on a count of 1. This distribution across 6 distinct art units means that the 8 pending office actions are subject to the standards of multiple specialized groups. Practitioners should tailor their responses to the specific expectations of these 8 different examiners to advance the Mirati Therapeutics Inc. portfolio. Coordinating across 6 distinct art units will be essential for maintaining a unified patent strategy.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §102 only | 3 (30%) |
| §112 only | 2 (20%) |
| Double-patenting + other | 3 (30%) |
| Multi-statute (no §101) | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 88.7% | +10.2% |
| KENYON, JOHN S | 1 | 79.7% | +18.3% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
| JOHANNSEN, DIANA B | 1 | 53.2% | +42.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19045764 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18694848 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | WILLIS, DOUGLAS M | — |
| 18572110 | Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors | INAM, SAHAR | — |
| 18543421 | COMBINATION THERAPIES | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286961 | KRAS G12C INHIBITORS | SEITZ, ANTHONY JOSEPH | 49d overdue |
| 18229662 | QUINAZOLINE PAN-KRas INHIBITORS | TOWNSLEY, SARA ELIZABETH | 9d |
| 18875584 | PRODRUGS OF PAN-KRAS INHIBITORS | WELLS, LAUREN QUINLAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286961 | KRAS G12C INHIBITORS | SEITZ, ANTHONY JOSEPH | 49d overdue |
| 18229662 | QUINAZOLINE PAN-KRas INHIBITORS | TOWNSLEY, SARA ELIZABETH | 9d |
| 18032492 | METHODS FOR TREATMENT OF LUNG CANCERS | JOHANNSEN, DIANA B | 40d |
| 19045764 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18878118 | SALTS OF SOS1 INHIBITORS | KENYON, JOHN S | — |
| 18875584 | PRODRUGS OF PAN-KRAS INHIBITORS | WELLS, LAUREN QUINLAN | — |
| 18658666 | Substituted Quinoxalines | LEE, CHIHYI NMN | — |
| 18694848 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1629 | 2 |
| 1625 | 1 |
| 1624 | 1 |
| 1699 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19045764 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112DP | Non-Final OA | — | Pending | Feb 05, 2025 |
| 18878118 | SALTS OF SOS1 INHIBITORS | KENYON, JOHN S | — | §112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18875584 | PRODRUGS OF PAN-KRAS INHIBITORS | WELLS, LAUREN QUINLAN | 1625 | §102§103§112 | Non-Final OA | — | Pending | Dec 16, 2024 |
| 18658666 | Substituted Quinoxalines | LEE, CHIHYI NMN | — | §102§103§112DP | Non-Final OA | — | Pending | May 08, 2024 |
| 18694848 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18572110 | Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors | INAM, SAHAR | 1622 | §102 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18543421 | COMBINATION THERAPIES | JARRELL, NOBLE E | 1699 | §103§112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18286961 | KRAS G12C INHIBITORS | SEITZ, ANTHONY JOSEPH | 1629 | §101DP | Final Rejection | 49d overdue | Pending | Oct 13, 2023 |
| 18229662 | QUINAZOLINE PAN-KRas INHIBITORS | TOWNSLEY, SARA ELIZABETH | 1629 | §102 | Non-Final OA | 9d | Pending | Aug 02, 2023 |
| 18032492 | METHODS FOR TREATMENT OF LUNG CANCERS | JOHANNSEN, DIANA B | 1682 | §102 | Final Rejection | 40d | Pending | Apr 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial